Experiences from daily practice of upadacitinib treatment on atopic dermatitis with a focus on hand eczema: Results from the <scp>BioDay</scp> registry

Abstract

Upadacitinib can be an effective treatment for patients with AD and concomitant HE in daily practice. Future studies should focus on the effectiveness of upadacitinib on chronic HE, especially on the different etiological subtypes of HE, including HE in non-atopic individuals.